FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
FibroBiologics (Nasdaq: FBLG) reported promising results from its artificial thymus organoid program. The technology demonstrated that fibroblasts and thymus-derived cell organoids can maintain functionality for over 50 days after transplantation, showing vascularization and generating diverse mature T cells in animal models. The organoids produced fully mature T cells with various differentiation capabilities, including CD4, CD8, T-regulatory, and gamma delta T cells. The artificial thymus also generates T cells with diverse TCR-beta chains for broad antigen recognition, potentially supporting immune function in patients with immune dysregulation or post-chemotherapy conditions.
FibroBiologics (Nasdaq: FBLG) ha riportato risultati promettenti dal suo programma di organoidi timici artificiali. La tecnologia ha dimostrato che i fibroblasti e gli organoidi deriviati dal timo possono mantenere la funzionalità per oltre 50 giorni dopo il trapianto, mostrando vascularizzazione e generando diverse cellule T mature in modelli animali. Gli organoidi hanno prodotto cellule T completamente mature con varie capacità di differenziazione, inclusi CD4, CD8, cellule T regolatorie e cellule T gamma delta. Il timus artificiale genera inoltre cellule T con catene TCR-beta diverse per un ampio riconoscimento degli antigeni, potenzialmente supportando la funzione immunitaria nei pazienti con disfunzione immunitaria o condizioni post-chemioterapia.
FibroBiologics (Nasdaq: FBLG) informó resultados prometedores de su programa de organoides de timo artificial. La tecnología demostró que los fibroblastos y los organoides derivados del timo pueden mantener la funcionalidad durante más de 50 días después del trasplante, mostrando vascularización y generando diversos linfocitos T maduros en modelos animales. Los organoides produjeron linfocitos T completamente maduros con diversas capacidades de diferenciación, incluyendo CD4, CD8, células T reguladoras y células T gamma delta. El timo artificial también genera linfocitos T con diferentes cadenas TCR-beta para un amplio reconocimiento de antígenos, lo que podría apoyar la función inmune en pacientes con disfunción inmune o condiciones posteriores a la quimioterapia.
FibroBiologics (Nasdaq: FBLG)는 인공 흉선 오르가노이드 프로그램의 유망한 결과를 보고했습니다. 이 기술은 섬유아세포와 흉선 유래 세포 오르가노이드가 이식 후 50일 이상 기능을 유지할 수 있음을 보여주었으며, 혈관화를 나타내고 동물 모델에서 다양한 성숙 T 세포를 생성했습니다. 오르가노이드는 CD4, CD8, 조절 T 세포 및 감마 델타 T 세포를 포함한 다양한 분화 능력을 가진 완전한 성숙 T 세포를 생성했습니다. 인공 흉선은 또한 다양한 TCR-베타 체인을 가진 T 세포를 생성하여 광범위한 항원 인식을 가능하게 하며, 면역 조절 장애나 화학요법 후 상태에 있는 환자의 면역 기능을 지원할 수 있습니다.
FibroBiologics (Nasdaq: FBLG) a rapporté des résultats prometteurs de son programme d'organoïdes thymiques artificiels. La technologie a démontré que les fibroblastes et les organoïdes dérivés du thymus peuvent maintenir leur fonctionnalité pendant plus de 50 jours après la transplantation, montrant une vascularisation et générant diverses cellules T matures dans des modèles animaux. Les organoïdes ont produit des cellules T pleinement matures avec diverses capacités de différenciation, y compris CD4, CD8, cellules T régulatrices et cellules T gamma delta. Le thymus artificiel génère également des cellules T avec des chaînes TCR-beta diverses pour une large reconnaissance des antigènes, ce qui pourrait soutenir la fonction immunitaire chez les patients présentant une dysrégulation immunitaire ou des conditions post-chimio.
FibroBiologics (Nasdaq: FBLG) berichtete über vielversprechende Ergebnisse aus seinem Programm für künstliche Thymus-Organoide. Die Technologie zeigte, dass Fibroblasten und vom Thymus abgeleitete Zellorganoide die Funktionalität über 50 Tage nach der Transplantation aufrechterhalten können, vaskularisiert werden und in Tiermodellen verschiedene reife T-Zellen erzeugen. Die Organoide produzierten vollständig reife T-Zellen mit unterschiedlichen Differenzierungsfähigkeiten, einschließlich CD4, CD8, T-regulatorische Zellen und gamma delta T-Zellen. Der künstliche Thymus generiert auch T-Zellen mit unterschiedlichen TCR-beta-Ketten für eine breite Antigen-Erkennung, was potenziell die Immunfunktion bei Patienten mit Immunregulationsstörungen oder nach Chemotherapie unterstützen kann.
- Successful demonstration of organoid functionality for over 50 days post-transplantation
- Achievement of vascularization in artificial thymus organoids
- Successful generation of diverse mature T cells with multiple differentiation capabilities
- Development of T cells with diverse TCR-beta chains for broad antigen recognition
- None.
Insights
The artificial thymus organoid technology shows remarkable progress with 50+ days of post-transplant functionality and successful vascularization in animal models. The ability to generate diverse T cell populations (CD4, CD8, T-regulatory and gamma delta) with varied TCR-beta chains represents a significant technical achievement in immunotherapy development.
The technology's potential impact on treating immune dysregulation conditions, particularly in post-chemotherapy patients and age-related immune decline, could open substantial market opportunities. However, the early-stage nature of this research, being still in animal models, means commercialization is likely several years away. The comprehensive immune cell generation capability could position this technology as a superior alternative to current immunotherapies, but clinical validation will be important for market acceptance.
This development strengthens FibroBiologics' intellectual property portfolio in the rapidly growing immunotherapy market, projected to reach
However, investors should note that clinical trials and regulatory approvals are still pending, making this a long-term value proposition rather than an immediate revenue generator.
HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced promising new findings from its artificial thymus organoid program. Recent results from the artificial thymus organoid program showed that fibroblasts and thymus-derived cell organoids can persist and function for over 50 days post-transplantation, with vascularization and the generation of a diverse array of mature T cells in animal models.
The artificial thymus organoid has shown an ability to support distinct vascularization, critical for sustained functionality in vivo, while producing fully mature T cells expressing T cell receptors (TCR). Fully mature T cells differentiate into various types of cells, including CD4, CD8, T-regulatory, and gamma delta T cells, and contribute to a well-rounded immune response. The artificial thymus organoid also produces T cells with diverse TCR-beta chains that enable the recognition of a broad spectrum of antigens.
"This data further supports our unique approach to using fibroblast-based organoids as potential therapeutics. Our findings to date underscore the potential of our artificial thymus organoid to restore and enhance immune function," said Hamid Khoja, Ph.D., Chief Scientific Officer. "The diverse TCR-beta repertoire, in combination with extended organoid functionality and vascularization, may provide an effective immune support platform for patients facing immune dysregulation, such as those with age-related immune decline or who have undergone chemotherapy. We are excited by this prospect and will continue our work to advance this technology toward clinical application."
"We believe these findings set the stage for revolutionary advancements in immunotherapy," said Pete O’Heeron, Founder and Chief Executive Officer. "By potentially offering a fibroblast-based organoid approach capable of generating a wide array of mature and functional T cells, we aim to provide patients with a safer, more effective option than currently utilized immune modulation and restoration therapies."
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential and capabilities of fibroblasts and artificial thymus organoids to persist and function post-transplantation, with vascularization and the generation of a diverse array of mature T cells, and to produce T cells with diverse TCR-beta chains, the potential of artificial thymus organoids to restore and enhance immune function and to provide for revolutionary advancements in immunotherapy, and a safer, more effective option than currently utilized immune modulation and restoration therapies. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (b) the unpredictable relationship between R&D and preclinical results and clinical study results; (c) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business, and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a cell therapy and regenerative medicine company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
Investor Relations:
Nic Johnson
Russo Partners
212-845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
General Inquiries:
info@fibrobiologics.com
FAQ
What are the key findings of FibroBiologics (FBLG) artificial thymus organoid program in 2024?
What types of T cells can FibroBiologics' (FBLG) artificial thymus organoid produce?
How long can FibroBiologics' (FBLG) artificial thymus organoids maintain functionality after transplantation?
